Document is current
Any future updates will be listed below
-
Authors
Akula, Vinita
Chen, Lily
Acikgoz, Yusuf
Klein, Katherine
Yavuz, Betul Gok
Cevik, Lokman
Demir, Tarik
Manne, Ashish
Sahin, Ilyas
Kaseb, Ahmed
Hasanov, Elshad
- License Information
-
More Information
Article History
Received: 23 September 2024
Accepted: 24 February 2025
First Online: 6 March 2025
Competing interests
: A.K. reports receiving grants or contracts from Roche Genentech, Merck, Exelexis, Eisai, Henguri, AdaptImmune. Tvardi, and BMS and consulting fees from Roche Genentech, Merck, Exelexis, Eisai, and BMS. A.M. reports receiving consulting fees from Pfizer and AstraZeneca. E.H. reports receiving OSUCCC-Pelotonia startup funds and honoraria from Target Oncology, and participating on advisory boards for Telix Pharmaceuticals, Pfizer, and Eisai. All other authors report no conflicts of interest.
